Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016

  • ID: 3743742
  • Drug Pipelines
  • 49 pages
  • Global Markets Direct
1 of 6
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016

Summary

‘Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Review, H1 2016’, provides in depth analysis on Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted pipeline therapeutics.

The report provides comprehensive information on the Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24)
- The report reviews Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics and enlists all their major and minor projects
- The report assesses Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6
List of Tables

List of Figures

Introduction

Report Coverage

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) Overview

Therapeutics Development

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Stage of Development

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Therapy Area

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Indication

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Products under Development by Companies

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Companies Involved in Therapeutics Development

FibroGen, Inc.

RXi Pharmaceuticals Corporation

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Drug Profiles

FG-3019 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLX-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RNAi Oligonucleotide to Inhibit CTGF for PVR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXI-209 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Dormant Projects

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Discontinued Products

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) - Featured News & Press Releases

Apr 19, 2016: RXi Pharmaceuticals Fortifies its Novel RNAi Patent Portfolio with Notice of Allowance for Lead Clinical Candidate RXI-109

Mar 28, 2016: RXi Pharmaceuticals to Present at the Oligonucleotide Therapeutics and Delivery Conference

Mar 11, 2016: FibroGen Announces Publication of Phase 2 Study Results Supporting the Potential of FG-3019 to Treat Patients With Idiopathic Pulmonary Fibrosis

Jan 27, 2016: FibroGen Announces Early Phase 2 Data From a Clinical Study of FG-3019 in Combination With Chemotherapy as Neoadjuvant in Locally Advanced, Unresectable Pancreatic Cancer

Jan 06, 2016: FibroGen Enrolls First Patients in Phase 2 Clinical Study of Anti-Fibrotic Drug Candidate FG-3019 for the Treatment of Duchenne Muscular

Nov 05, 2015: Edison Initiates Coverage on RXi Pharmaceuticals

Nov 05, 2015: RXi Pharmaceuticals Announces the Initiation of a Phase 1/2 Trial in Ophthalmology with RXI-109 for Retinal Scarring

Oct 15, 2015: RXi Pharmaceuticals Announces Positive Interim Results in Phase 2a Dermatology Program with RXI-109

Oct 12, 2015: RXi Pharmaceuticals to Present at Premier Scientific Plastic Surgery Meeting

Oct 05, 2015: RXi Pharmaceuticals Bolsters Protection for its Novel Self-Delivering RNAi Platform with Notice of Allowance from USPTO

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by FibroGen, Inc., H1 2016

Pipeline by RXi Pharmaceuticals Corporation, H1 2016

Dormant Projects, H1 2016

Discontinued Products, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6
Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.Our latest report Connective Tissue Growth Factor – Pipeline Review, H1 2016, outlays comprehensive information on the Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) Connective tissue growth factor (CTGF), also known as CCN2 is a matricellular protein of the CCN family of extracellular matrix-associated heparin-binding proteins. CTGF plays an important role in promoting fibroblast proliferation, migration, adhesion, and extracellular matrix formation, and its overproduction plays a major role in pathways that lead to fibrosis (TGF-beta-dependent). This includes fibrosis of major organs, fibroproliferative diseases, and scarring. CTGF also plays an important role in the extracellular matrix remodeling that occurs in normal physiological processes such as embryogenesis, implantation, and wound healing. The molecules developed by Companies in Phase II, IND/CTA Filed and Preclinical stages are 2, 1 and 3 respectively.

Furthermore, this report also reviews key players involved in Connective Tissue Growth Factor (Insulin-Like Growth Factor-Binding Protein 8 or Hypertrophic Chondrocyte-Specific Protein 24) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Driven by data built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
FibroGen, Inc.
RXi Pharmaceuticals Corporation
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll